Azacytidine has been used as prophylactic or preemptive therapy after allogeneic transplantation in myeloid malignancies, but its use is not yet consensual. We retrospectively analyzed 32 patients in this setting, to evaluate tolerability and outcomes. These results are promising, with a low rate of relapse in prophylactic therapy and a good rate of disease stabilization in preemptive therapy.
Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation / Marini, C.; Brissot, E.; Bazarbachi, A.; Dulery, R.; Sestili, S.; Battipaglia, G.; Mediavilla, C.; Paviglianiti, A.; Belhocine, R.; Isnard, F.; Lapusan, S.; Adaeva, R.; Bannet, A.; van de Wiegert, Z.; Vekhoff, A.; Ledraa, T.; Legrand, O.; Labopin, M.; Bonnin, A.; Ruggeri, A.; Malard, F.; Mohty, M.. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - 20:6(2020), pp. 377-382. [10.1016/j.clml.2019.10.011]
Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation
Battipaglia G.;
2020
Abstract
Azacytidine has been used as prophylactic or preemptive therapy after allogeneic transplantation in myeloid malignancies, but its use is not yet consensual. We retrospectively analyzed 32 patients in this setting, to evaluate tolerability and outcomes. These results are promising, with a low rate of relapse in prophylactic therapy and a good rate of disease stabilization in preemptive therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2152265019320592-main.pdf
solo utenti autorizzati
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
277.44 kB
Formato
Adobe PDF
|
277.44 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
